News & Events

Hengrui Pharma and Kailera Therapeutics Report Positive Topline Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531

July 15, 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 85th Scientific Sessions

June 16, 2025

Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors

June 5, 2025

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

January 27, 2025

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

January 13, 2025

Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

January 8, 2025

Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer

November 12, 2024

Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions

October 1, 2024